Robeco Institutional Asset Management B.V. Purchases 68,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Robeco Institutional Asset Management B.V. lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 61.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 179,084 shares of the biotechnology company's stock after purchasing an additional 68,000 shares during the period. Robeco Institutional Asset Management B.V. owned 0.08% of ADMA Biologics worth $3,580,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Quest Partners LLC bought a new position in ADMA Biologics during the 2nd quarter worth $29,000. EntryPoint Capital LLC bought a new stake in ADMA Biologics in the 1st quarter valued at about $31,000. CWM LLC grew its holdings in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of ADMA Biologics during the second quarter valued at about $93,000. Finally, USA Financial Formulas lifted its holdings in ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock worth $136,000 after buying an additional 539 shares during the period. 75.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Young Kwon sold 60,000 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares of the company's stock, valued at $4,408,712.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the business's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on ADMA shares. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research report on Friday. Finally, HC Wainwright upped their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of "Buy" and a consensus target price of $21.25.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock traded up $2.90 on Friday, hitting $22.62. The stock had a trading volume of 9,717,443 shares, compared to its average volume of 3,667,173. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.52. The company's 50 day moving average price is $18.12 and its 200 day moving average price is $13.84. The stock has a market cap of $5.27 billion, a price-to-earnings ratio of 80.79 and a beta of 0.64. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. ADMA Biologics's revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.02) EPS. On average, research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.